No diseases are being studied. Amount of bone marrow and visceral fat, thrombocyte function.
Conditions
Interventions
Transwomen will receive a GnRH analogue every 4 weeks from week 0 until week 20 and estradiol from week 6 and cyproterone acetate from week 20 until the end of the study (week 58). Transmen will recei
Sponsors
Amsterdam UMC, location VUmc
Eligibility
Inclusion criteria
Inclusion criteria: ? Diagnosed with gender dysphoria according to DSM V (female-to-male or male-to-female) ? Age between 18 and 50 years ? Female-to-male transgenders need to be premenopausal ? Starting cross-sex hormone treatment
Exclusion criteria
Exclusion criteria: ? Previous use of cross-sex hormones ? Contraindications to MRI scanning ? Participation in other studies (with exception of the ENIGI study) ? Use of bone-modifying or adipose tissue-modifying drugs, current or in history (bisphosphonates, estrogen receptor modulators, calcium regulating agents, corticosteroids) ? Bone or bone marrow diseases, current or in history (metabolic, malignancy, infectious, mechanic, bone marrow diseases) ? Platelet count <120*109/l ? History of non-traumatic major bleeding ? Known bleeding diathesis ? Conditions which require antiplatelet therapy ? Usage of antiplatelet therapy ? Chronic usage of medication known to influence platelet function (e.g. DOAC’s, NSAIDs, warfarin)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in vertebral marrow fat fraction measured by MRI quantitative chemical shift imaging (QCSI), changes in visceral fat, measured by MRI and DXA. | — |
Secondary
| Measure | Time frame |
|---|---|
| ? Bone turnover markers (Ctx, P1NP, osteocalcin) ? Adiponectin and leptin. ? Changes in inflammation markers (HsCRP, IL-6, G-CSF) ? Changes in platelet activation, measured by PFA Closure Time, PFA Total Volume, PFA Initial Flow Rate, Plasma Thromboxane B2, Flow-cytometry among which p-selectin | — |
Contacts
Public ContactMarieke Tebbens
Amsterdam UMC, location VUmc
Outcome results
None listed